A Phase 3, Double-Blind, Randomized, Long Term, Placebo-Controlled Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

Grants and Contracts Details

StatusFinished
Effective start/end date3/15/16 → 8/8/24

Funding

  • Intercept Pharmaceuticals Incorporated: $287,451.00